Management Team

CHO Pharma is composed of a number of international professionals with experience in management and pharmaceutical R&D. Currently, more than 40 scientists with expertise in carbohydrate-based technology and biopharmaceutical development are working in the company, and we are in the process of expansion by recruiting the best professionals and scientists to join the company. The following are some key members.

Chairman and President Chao-Long Chen,MD,PhD (Hon.)

Professor Chao-Long Chen is a pioneer liver transplant surgeon who performed the first successful liver transplantation in Asia in 1984, and by 2017, has accomplished 1700 more. He is a graduate of the Kaohsiung Medical University and did his surgical training at the Chang Gung Memorial Hospital, Taiwan and the Hospital for Sick Children, Toronto, Canada. He later obtained fellowship training in liver transplantation with the renowned Professor Thomas Starzl at the University of Pittsburgh, USA. He is a recipient of various honors and distinctions, both locally and internationally. He became Professor of Surgery in 1993 and subsequently has been bestowed with Honorary PhD and Professor by acclaimed international universities. In 1994, he performed the first living donor liver transplantation in Taiwan and was bestowed with the National Award for Outstanding Contribution in Science and Technology in 1996. He did the first split liver transplantation in Asia in 1997. He started the adult living donor liver transplantation in Taiwan in 1999. Further, he performed the first dual graft living donor liver transplantation in Taiwan in 2002, has pioneered routine microsurgical biliary reconstruction in the world in 2006 and performed the first segment 2 monosegment living donor liver transplantation in Taiwan in 2013. He became Superintendent of the Kaohsiung Chang Gung Memorial Hospital in 2003-2015 and has become Superintendent Emeritus since October 2015. He has published more than 460 SCI-cited scientific articles and has lectured in more than 300 international and overseas congresses, and honorary and visiting professorships. He was appointed in the advisory board of Center for Asia Pacific Policy of USA based RAND Corporation in 2016. He is an associate editor of the American Journal of Transplantation and serves in the editorial board of Annals of Surgery, Transplantation, Liver Transplantation, etc. He was elected as Academician of the prestigious Chinese Academy of Engineering in 2007 and as President-elect of the International Living Donor Liver Transplantation Study Group in 2017. He remains director of one of the leading global centers in living donor liver transplantation.

Senior Technology Advisor
Lan-Bo Chen, Ph.D.

Dr. Chen is Professor Emeritus of Pathology at Harvard Medical School. He received his B.S. in chemistry from National Taiwan University, Ph.D. in cell biology from the Massachusetts Institute of Technology, postdoctoral training under Dr. James D. Watson (Nobel Laureate) at Cold Spring Harbor Laboratories, was recruited by Dr. Baruj Benacerraf (Nobel Laureate) to Harvard Medical School and elected as an academician of the Academia Sinica of Taiwan. He is the author of over 250 academic publications and is the founder of several successful biotechnology companies and ventures, including Fuji ImmunoPharmaceuticals Corp. and Shionogi BioResearch Corp. (both with Nobel laureate Dr. Susumu Tonegawa); Caxton Life Science Partners; Taiwan Global BioFund; TaiMed Biologics; Mevion Medical Systems; Cancer BioScience; Cancer Genetics; Kava Pharmaceuticals; SinglePixel BioMedical; Quercegen Pharma; Madrigal/Synta Pharmaceuticals and Sequential Medicine. Dr. Chen has served as a Senior Consultant for numerous large pharmaceutical firms, and has led the development or consulted for more than a dozen drugs and drug candidates.

Executive Vice President, R&D
Nan-Horng Lin, Ph.D.

Dr. Nan-Horng Lin received his Ph.D. degree from Indiana University, USA. With more than 30 years of experience in pharmaceutical industry, Dr. Lin specializes in synthetic organic chemistry, medicinal chemistry, new target identification, hit to lead optimization and general research management in pharmaceutical and CRO companies. Prior to joining CHO Pharma, Dr. Lin served as the Director of Institute of Pharmaceutics of Development Center for Biotechnology (DCB), Senior Vice President of Crown Bioscience Inc., Chief Scientific Officer of Medicilon Inc. and Senior Group Leader and Research Fellow of Abbott Laboratories. During his tenure with Abbott, Dr. Lin led several R&D projects and had successfully identified four clinical candidates which had entered Phase II and Phase III trials. Dr. Lin experiences in identifying clinical candidates as well as building and leading highly productive research team in drug discovery and CRO organizations. Now, Dr. Lin brings his experience in R&D technology and his business acumen to CHO Pharma Inc. and continues to focus on producing innovative and niche products.